Trial results

Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.

NCT07588438 on ClinicalTrials.gov · last registry update 2026-05-19

An unusually large phase 4: 160 participants, more than double the 72 typical for the stage. Due to report 10 August 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Mean Percent Change From Baseline in Body Weight at 52 Weeks. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

RECRUITING

Phase

P4

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Las Rías Medical Center

Sponsor type

Other

Enrollment

160

Started

2026-07-27

Primary completion

2027-08-10 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Percent Change From Baseline in Body Weight at 52 Weeks.

Conditions studied

Obesity · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.